Alkermes Plc Investor Event to Review Orexin Portfolio Strategy Transcript - Thomson StreetEvents

Alkermes Plc Investor Event to Review Orexin Portfolio Strategy Transcript

Alkermes Plc Investor Event to Review Orexin Portfolio Strategy Transcript - Thomson StreetEvents
Alkermes Plc Investor Event to Review Orexin Portfolio Strategy Transcript
Published Oct 09, 2024
38 pages (26792 words) — Published Oct 09, 2024
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ALKS.OQ conference call or presentation 9-Oct-24 2:00pm GMT

  
Brief Excerpt:

...Good morning, everyone. I'm Sandy Coombs, I lead Investor Relations here at Alkermes. I'm happy to welcome you all today here in the room and on the webcast. I know it's a busy time of year, so thank you making for making the time to learn a little bit more about Alkermes direction portfolio. Some housekeeping items for today, there will be two opportunities for Q&A during our roundtable panel with Dr. Maski, from Boston Children's; and Dr. Plante, from the University of Wisconsin-Madison; Monica Gow, Co-founder of Wake Up, Narcolepsy is here to join us, and we're fortunate to have them here with us. So please take advantage of the opportunity. During today's presentation, we will be making forward-looking statements, so please take a look at our so please take a look at (laughter) our SEC filings for important risk factors that could cause our actual results to differ materially from those expressed or implied in our forward-looking statements. We undertake no obligation to update or revise...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Alkermes Plc
Ticker
ALKS.OQ
Time
2:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Joseph Thome - TD Cowen - Analyst : Hey, there -- (inaudible) CD Cowen. Thank you for taking my question. You mentioned earlier that the lack of efficacy of current available agents. I guess when you look at the MWT, is there a sweet spot for efficacy on that? Because obviously the orexin classes getting towards the end of and the company mentioned the opportunity for flexible dosing. Is that when you would use like full dosing? Or how do you and corporate?

Question: Joseph Thome - TD Cowen - Analyst : Hi there. Jo from TD Cowen. Thank you for the presentation. I actually have a question on the last portion of the presentation in terms of the additive benefit in ADHD. I guess how are you thinking about the actual need for that non-stimulant option, given that it didn't look like the nonstimulant actually provide additional benefit in the rodent models above what the Orexin was doing, kind of like the Orexin was doing all the heavy lifting? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 09, 2024 / 2:00PM, ALKS.OQ - Alkermes Plc Investor Event to Review Orexin Portfolio Strategy And then second question on some of these combinations. How easy is it to model DDIS, and AES, and preclinical models with Orexin? Obviously, you're seeing some added benefit in depression, but how much can you de risk the tolerability profile of this?

Table Of Contents

Alkermes Plc Q1 2025 Earnings Call Transcript – 2025-05-01 – US$ 106.00 – Edited Transcript of ALKS.OQ earnings conference call or presentation 1-May-25 12:00pm GMT

Alkermes Plc at TD Cowen Healthcare Conference Transcript – 2025-03-05 – US$ 54.00 – Edited Transcript of ALKS.OQ presentation 5-Mar-25 2:50pm GMT

Alkermes Plc Q4 2024 Earnings Call Transcript – 2025-02-12 – US$ 54.00 – Edited Transcript of ALKS.OQ earnings conference call or presentation 12-Feb-25 1:00pm GMT

Alkermes Plc at JPMorgan Healthcare Conference Transcript – 2025-01-15 – US$ 54.00 – Edited Transcript of ALKS.OQ presentation 15-Jan-25 7:15pm GMT

Alkermes Plc Q3 2024 Earnings Call Transcript – 2024-10-24 – US$ 54.00 – Edited Transcript of ALKS.OQ earnings conference call or presentation 24-Oct-24 12:00pm GMT

Alkermes Plc at Morgan Stanley Global Healthcare Conference Transcript – 2024-09-04 – US$ 54.00 – Edited Transcript of ALKS.OQ presentation 4-Sep-24 6:35pm GMT

Alkermes Plc at Goldman Sachs Global Healthcare Conference Transcript – 2024-06-11 – US$ 54.00 – Edited Transcript of ALKS.OQ presentation 11-Jun-24 2:40pm GMT

Alkermes Plc at JPMorgan Healthcare Conference Transcript – 2024-01-10 – US$ 54.00 – Edited Transcript of ALKS.OQ presentation 10-Jan-24 7:15pm GMT

Alkermes Plc Q3 2023 Earnings Call Transcript – 2023-10-25 – US$ 54.00 – Edited Transcript of ALKS.OQ earnings conference call or presentation 25-Oct-23 12:00pm GMT

Alkermes Plc Mural Oncology Call Transcript – 2023-10-17 – US$ 54.00 – Edited Transcript of ALKS.OQ conference call or presentation 17-Oct-23 3:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Alkermes Plc Investor Event to Review Orexin Portfolio Strategy Transcript" Oct 09, 2024. Alacra Store. May 04, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Alkermes-Plc-Investor-Event-to-Review-Orexin-Portfolio-Strategy-T16130825>
  
APA:
Thomson StreetEvents. (2024). Alkermes Plc Investor Event to Review Orexin Portfolio Strategy Transcript Oct 09, 2024. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Alkermes-Plc-Investor-Event-to-Review-Orexin-Portfolio-Strategy-T16130825>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.